This study was designed to examine the relationship between epicardial ST change (EpST) and regional myocardial blood flow (RMBF) following coronary occlusion and extent of myocardial infarction (MI) in awake dogs. Fifteen min and two hr after coronary occlusion simultaneous measurements of EpST and RMBF were made. Six days later histologic MI and RMBF were determined in transmural myocardial s...

A review of 6040 consecutive exercise tests yielded 106 patients without previous myocardial infarction (MI) who had exercise-induced ST elevation (greater than or equal to 0.5 mm in a 15-lead ECG system). In 46, ST elevation was correlated with left ventriculography and coronary angiography. Coronary artery disease (CAD) (greater than or equal to 70% narrowing) was detected in 40 of 46 patient...

AIMS Serial forecasts of final myocardial infarct (MI) size during fibrinolytic treatment (Rx) of ST-elevation MI would allow the identification of high-risk patients with a predicted major loss of viable myocardium, at a point when treatment may still be modified. We investigated a model for such forecasting, using time and the ECG. METHODS AND RESULTS We collected 234 patients with ST-eleva...

background: more than half of myocardial infracted (mi) patients have no conventional risk factors. regarding the belief that opium addiction has a protective effect on heart diseases, addiction prevalence has unfortunately increased in recent years. this study was conducted to investigate the effect of opium addiction on patients with acute myocardial infarction. methods: this case-control stu...

Antagonists of the platelet fibrinogen receptor glycoprotein IIb/IIIa are potent inhibitors of platelet function and provide marked protection from ischemic events in patients undergoing PCI. These agents are also of benefit in patients with unstable angina or non-ST segment elevation myocardial infarction (MI) and provide a 9% reduction in the combined endpoint of 30-day death or MI. This bene...

BACKGROUND AND OBJECTIVES Pentraxin 3 (PTX3) was shown to be elevated in the acute phase of acute myocardial infarction (AMI) and to have prognostic significance in AMI patients. The aim of this study was to estimate whether the value of PTX3 could be used as a prognostic biomarker, with the global registry of acute coronary events (GRACE) risk assessment tool, in patients with acute coronary s...

Ticagrelor (Brilinta; AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA) is a direct acting, reversible, oral P2Y12 inhibitor.1) In the PLATelet inhibition and patient Outcomes (PLATO) study, compared to clopidogrel (Plavix; Bristol-Myers Squibb/Sanofi Pharmaceuticals, Bridgewater, NJ, USA), ticagrelor reduced the rate of death from vascular causes, myocardial infarction (MI), or stroke in pa...

To cite: Sidhu MS, Aggarwal K, Fay WP. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/bcr-2012008087 DESCRIPTION Right ventricular (RV) myocardial infarction (MI) often accompanies inferior left ventricular (LV) MI. However, isolated RV MI is very rare. A man (age range 30–40 years) presented with acute chest pain. ECG revealed ST segment elevation in leads V1–V4 (fi...

BACKGROUND Platelet activation is a hallmark of acute coronary syndromes. Numerous lines of evidence suggest a mechanistic link between von Willebrand factor or platelet hyperfunction and myocardial damage in patients with acute coronary syndromes. Thus, we assessed whether platelet function under high shear rates (collagen adenosine diphosphate closure times [CADP-CTs]) measured with the plate...